Hospital
Oakwood Healthcare, INC.
Oakwood Healthcare, INC. was paid $165.61M by Medicaid between Jan 2018 and Dec 2024, across 774 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoOAKWOOD HEALTHCARE, INC.
DEARBORN, MI 48124
DEARBORN, MI 48124
33aNPI1740230119assigned 05/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$165.61M
24GClaims7,046,474
24DCodes billed774
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#3 of 86
Median peer was paid$21.55M
This provider vs. median7.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 476,736 | $17.75M | |
| 2019 | 980,596 | $19.91M | |
| 2020 | 860,406 | $20.52M | |
| 2021 | 1,156,997 | $26.80M | |
| 2022 | 1,262,017 | $29.82M | |
| 2023 | 1,326,805 | $29.26M | |
| 2024incomplete | 982,917 | $21.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 106,972 | 100,138 | $37.16M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.0% | 42,647 | 41,543 | $8.29M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.3% | 90,360 | 81,911 | $5.48M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 62,220 | 53,769 | $5.21M |
| G0378 | Hospital observation service, per hour | 3.0% | 25,890 | 23,262 | $5.04M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.2% | 26,883 | 26,057 | $3.69M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.9% | 199,167 | 198,360 | $3.20M |
| 47562 | 1.7% | 1,035 | 1,032 | $2.84M | |
| 80061 | Lipid panel | 1.6% | 260,578 | 259,402 | $2.61M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 262,078 | 259,310 | $2.50M |
| 93458 | 1.5% | 1,667 | 1,658 | $2.42M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 16,885 | 16,622 | $2.12M |
762 more codes
| 80053 | Comprehensive metabolic panel | 1.2% | 363,062 | $1.97M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 91,211 | $1.78M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 90,491 | $1.76M |
| 58558 | <1% | 1,209 | $1.65M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 32,096 | $1.62M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 18,368 | $1.55M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 447,082 | $1.49M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 28,880 | $1.40M |
| 59025 | Fetal non-stress test | <1% | 15,688 | $1.40M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16,995 | $1.29M |
| 71045 | Radiologic examination, chest; single view | <1% | 29,164 | $1.27M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 3,611 | $1.26M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 25,266 | $1.24M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,424 | $1.23M |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 214,623 | $1.21M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,994 | $1.20M |
| 82947 | <1% | 35,066 | $1.13M | |
| 82607 | <1% | 137,680 | $1.12M | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14,473 | $1.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 11,484 | $1.09M |
| 93975 | <1% | 10,257 | $1.08M | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 47,965 | $1.08M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,417 | $1.05M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 25,704 | $1.04M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,745 | $988K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 20,194 | $971K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,222 | $965K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 23,529 | $949K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,888 | $942K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 4,289 | $896K |
| 76830 | Ultrasound, transvaginal | <1% | 14,732 | $878K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 8,726 | $874K |
| 19083 | <1% | 1,092 | $864K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 24,325 | $805K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 59,078 | $805K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,452 | $788K |
| 95811 | <1% | 1,581 | $788K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 26,615 | $709K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 6,031 | $683K |
| 84439 | <1% | 129,563 | $678K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 13,633 | $657K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,090 | $644K |
| 76801 | <1% | 10,149 | $606K | |
| 83013 | <1% | 15,154 | $602K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 9,881 | $596K |
| 86003 | <1% | 7,343 | $537K | |
| 76770 | <1% | 9,304 | $524K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 20,544 | $505K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25,780 | $502K |
| 80074 | <1% | 18,751 | $497K | |
| 82728 | <1% | 61,685 | $492K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 5,201 | $492K |
| 82746 | <1% | 57,220 | $488K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,472 | $482K |
| 84466 | <1% | 59,769 | $445K | |
| 87631 | <1% | 11,063 | $436K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 20,328 | $430K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 3,184 | $429K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,112 | $417K |
| 86900 | <1% | 28,928 | $416K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 94,078 | $412K |
| 76642 | <1% | 10,238 | $412K | |
| 87480 | <1% | 37,459 | $409K | |
| 86803 | <1% | 47,606 | $409K | |
| 72141 | <1% | 3,069 | $408K | |
| 87660 | <1% | 36,805 | $399K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,712 | $393K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,703 | $387K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 788 | $385K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 90,892 | $382K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 22,205 | $381K |
| 87510 | <1% | 35,727 | $380K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 6,179 | $374K |
| 36415 | Collection of venous blood by venipuncture | <1% | 298,071 | $373K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 9,836 | $332K |
| 77066 | Tomosynthesis, mammo | <1% | 5,461 | $323K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,991 | $319K |
| 76536 | <1% | 5,732 | $294K | |
| 84403 | <1% | 19,108 | $293K | |
| 86769 | <1% | 11,787 | $289K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 355 | $287K |
| 90670 | <1% | 5,939 | $285K | |
| 83540 | <1% | 72,437 | $277K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 10,297 | $273K |
| 93798 | <1% | 4,196 | $272K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16,367 | $271K |
| 73221 | <1% | 1,828 | $265K | |
| 86480 | <1% | 7,195 | $264K | |
| 97161 | <1% | 2,984 | $260K | |
| 93970 | <1% | 2,859 | $258K | |
| 74178 | <1% | 1,383 | $254K | |
| 74174 | <1% | 1,735 | $254K | |
| 84702 | <1% | 61,316 | $250K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 20,290 | $244K |
| 72110 | <1% | 6,165 | $240K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,878 | $236K |
| 77065 | Tomosynthesis, mammo | <1% | 5,164 | $235K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,143 | $235K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,921 | $233K |
| 84481 | <1% | 22,481 | $223K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,734 | $206K |
| 77334 | <1% | 652 | $206K | |
| 74183 | <1% | 1,006 | $206K | |
| 70486 | <1% | 4,862 | $201K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 9,062 | $200K |
| 83970 | <1% | 8,602 | $194K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 126 | $194K |
| 85027 | <1% | 64,553 | $193K | |
| 70491 | <1% | 1,805 | $193K | |
| 87653 | <1% | 9,940 | $189K | |
| 77386 | <1% | 578 | $188K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,482 | $180K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13,924 | $179K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 10,564 | $176K |
| 93971 | <1% | 3,997 | $175K | |
| 86780 | <1% | 20,161 | $175K | |
| 77336 | <1% | 2,526 | $174K | |
| 83735 | <1% | 93,480 | $171K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 374 | $165K |
| 78226 | <1% | 1,028 | $161K | |
| 73564 | <1% | 4,938 | $157K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25,833 | $154K |
| 86696 | <1% | 13,931 | $153K | |
| 87340 | <1% | 27,116 | $153K | |
| 96367 | <1% | 5,377 | $150K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17,690 | $148K |
| 72131 | <1% | 3,097 | $148K | |
| 82043 | <1% | 41,968 | $142K | |
| 88184 | <1% | 1,895 | $142K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 360 | $136K |
| 87536 | <1% | 2,939 | $136K | |
| 83001 | <1% | 12,217 | $134K | |
| 77412 | <1% | 1,030 | $131K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13,408 | $128K |
| 86038 | <1% | 18,478 | $127K | |
| 87070 | <1% | 27,618 | $127K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,728 | $125K |
| 71250 | <1% | 2,256 | $124K | |
| 74018 | <1% | 4,465 | $120K | |
| 87077 | <1% | 25,220 | $119K | |
| 77080 | <1% | 1,941 | $117K | |
| 73130 | <1% | 5,908 | $117K | |
| 87186 | <1% | 23,650 | $117K | |
| 84146 | <1% | 10,406 | $117K | |
| 58661 | <1% | 42 | $116K | |
| 83655 | <1% | 16,474 | $115K | |
| 96415 | <1% | 2,342 | $112K | |
| 83002 | <1% | 10,108 | $111K | |
| 74022 | <1% | 2,769 | $111K | |
| 72197 | <1% | 559 | $110K | |
| 82670 | <1% | 6,480 | $109K | |
| 82652 | <1% | 5,203 | $108K | |
| 93351 | <1% | 405 | $108K | |
| 86235 | <1% | 3,295 | $107K | |
| 80081 | <1% | 2,806 | $103K | |
| 73030 | <1% | 5,581 | $102K | |
| 73630 | <1% | 6,032 | $102K | |
| 76881 | <1% | 1,698 | $101K | |
| 36430 | <1% | 1,011 | $101K | |
| 92523 | <1% | 953 | $100K | |
| 81001 | <1% | 78,625 | $99K | |
| 77072 | <1% | 1,724 | $99K | |
| 84153 | <1% | 9,012 | $97K | |
| 86695 | <1% | 12,676 | $97K | |
| 84402 | <1% | 6,880 | $96K | |
| 30520 | <1% | 119 | $96K | |
| 82627 | <1% | 7,137 | $95K | |
| 86762 | <1% | 11,579 | $93K | |
| 72082 | <1% | 1,677 | $93K | |
| 97165 | <1% | 2,616 | $91K | |
| 97162 | <1% | 1,525 | $90K | |
| 71271 | <1% | 1,511 | $87K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,323 | $87K |
| 82105 | <1% | 9,330 | $85K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 7,023 | $85K |
| 84550 | <1% | 34,336 | $84K | |
| 86147 | <1% | 2,024 | $83K | |
| 83021 | <1% | 8,279 | $82K | |
| 86706 | <1% | 13,629 | $82K | |
| 73610 | <1% | 4,104 | $80K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 48,103 | $75K |
| 82785 | <1% | 7,610 | $71K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,478 | $71K |
| 87634 | <1% | 1,885 | $71K | |
| 93925 | <1% | 623 | $70K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,973 | $70K |
| 86787 | <1% | 9,586 | $70K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,991 | $69K |
| 93017 | <1% | 4,058 | $69K | |
| 72050 | <1% | 1,433 | $69K | |
| 77300 | <1% | 336 | $69K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,181 | $67K |
| 10005 | <1% | 203 | $67K | |
| 72052 | <1% | 1,254 | $67K | |
| 93880 | <1% | 965 | $67K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 723 | $64K |
| 83880 | <1% | 12,531 | $63K | |
| 72100 | <1% | 1,731 | $62K | |
| 86140 | <1% | 22,676 | $61K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 891 | $60K |
| 81003 | <1% | 60,781 | $60K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 388 | $59K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 114 | $56K |
| 73502 | <1% | 2,671 | $56K | |
| 90651 | <1% | 763 | $55K | |
| 86850 | <1% | 26,590 | $55K | |
| 90716 | <1% | 1,885 | $54K | |
| 84144 | <1% | 4,250 | $54K | |
| 86376 | <1% | 6,216 | $53K | |
| 86592 | <1% | 22,063 | $53K | |
| 96417 | <1% | 1,352 | $53K | |
| 82784 | <1% | 6,195 | $52K | |
| 97116 | <1% | 4,710 | $52K | |
| 85610 | <1% | 66,150 | $52K | |
| 73110 | <1% | 2,624 | $51K | |
| 86431 | <1% | 15,150 | $49K | |
| 85652 | <1% | 33,903 | $49K | |
| 97166 | <1% | 1,164 | $48K | |
| 90686 | <1% | 4,645 | $47K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 2,845 | $46K |
| 88185 | <1% | 657 | $46K | |
| 80051 | <1% | 17,062 | $45K | |
| 87529 | <1% | 1,929 | $44K | |
| 96523 | <1% | 1,911 | $44K | |
| 86870 | <1% | 520 | $44K | |
| 84425 | <1% | 3,644 | $44K | |
| 86146 | <1% | 1,377 | $44K | |
| 31253 | <1% | 14 | $42K | |
| 86225 | <1% | 5,224 | $41K | |
| 86360 | <1% | 1,675 | $41K | |
| 70496 | <1% | 878 | $40K | |
| 83525 | <1% | 5,962 | $40K | |
| 82550 | <1% | 14,033 | $40K | |
| 83516 | <1% | 5,604 | $40K | |
| 74019 | <1% | 642 | $40K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 673 | $39K |
| 80076 | <1% | 16,209 | $39K | |
| 99195 | <1% | 690 | $39K | |
| 82565 | <1% | 31,526 | $38K | |
| 44970 | <1% | 12 | $38K | |
| 95806 | <1% | 471 | $38K | |
| 82533 | <1% | 3,965 | $38K | |
| 82248 | <1% | 21,685 | $38K | |
| 73562 | <1% | 2,253 | $37K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 540 | $37K |
| 86200 | <1% | 4,816 | $36K | |
| 85730 | <1% | 48,093 | $36K | |
| 76870 | <1% | 2,008 | $34K | |
| 86800 | <1% | 3,816 | $34K | |
| 72040 | <1% | 1,392 | $34K | |
| 86160 | <1% | 2,605 | $34K | |
| 72072 | <1% | 953 | $34K | |
| 84478 | <1% | 973 | $33K | |
| 88112 | <1% | 2,059 | $33K | |
| 82378 | <1% | 3,204 | $32K | |
| 82570 | <1% | 11,967 | $32K | |
| 76882 | <1% | 892 | $32K | |
| 84460 | <1% | 13,863 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,732 | $31K |
| 84450 | <1% | 13,947 | $31K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,658 | $30K |
| 30140 | <1% | 160 | $30K | |
| 90732 | <1% | 360 | $30K | |
| 87427 | <1% | 2,413 | $30K | |
| 87632 | <1% | 333 | $29K | |
| 81329 | <1% | 619 | $29K | |
| 10060 | <1% | 409 | $29K | |
| 88342 | <1% | 2,081 | $28K | |
| 84100 | <1% | 18,649 | $28K | |
| 73523 | <1% | 474 | $28K | |
| 73700 | <1% | 551 | $28K | |
| 82950 | <1% | 10,184 | $28K | |
| 73080 | <1% | 1,532 | $27K | |
| 73560 | <1% | 1,586 | $27K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,449 | $27K |
| 73590 | <1% | 2,213 | $27K | |
| 84445 | <1% | 865 | $26K | |
| 72070 | <1% | 718 | $26K | |
| 83690 | <1% | 36,829 | $26K | |
| 83615 | <1% | 10,165 | $25K | |
| 84520 | <1% | 25,290 | $24K | |
| 87046 | <1% | 2,422 | $24K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 552 | $24K |
| 86039 | <1% | 3,810 | $24K | |
| 76818 | <1% | 393 | $24K | |
| 82274 | <1% | 2,215 | $23K | |
| 78227 | <1% | 126 | $23K | |
| 73090 | <1% | 1,690 | $22K | |
| 88307 | <1% | 1,614 | $22K | |
| 82024 | <1% | 986 | $22K | |
| 86359 | <1% | 983 | $21K | |
| 84156 | <1% | 11,776 | $21K | |
| 86704 | <1% | 3,007 | $20K | |
| 86765 | <1% | 2,592 | $20K | |
| 85046 | <1% | 6,035 | $20K | |
| 86735 | <1% | 2,523 | $20K | |
| 82247 | <1% | 8,772 | $19K | |
| C1769 | Guide wire | <1% | 4,010 | $19K |
| 88304 | <1% | 4,245 | $19K | |
| 82150 | <1% | 6,477 | $19K | |
| 94726 | <1% | 344 | $18K | |
| 76825 | <1% | 65 | $18K | |
| 82677 | <1% | 1,452 | $18K | |
| 71101 | <1% | 663 | $18K | |
| 96411 | <1% | 498 | $18K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 13 | $18K |
| 82951 | <1% | 2,360 | $18K | |
| 86255 | <1% | 2,156 | $17K | |
| 72170 | <1% | 2,012 | $17K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 5,028 | $17K |
| 88142 | <1% | 1,221 | $16K | |
| 70360 | <1% | 551 | $16K | |
| 87147 | <1% | 4,864 | $16K | |
| 84165 | <1% | 2,818 | $15K | |
| 86304 | <1% | 1,391 | $15K | |
| 86901 | <1% | 27,587 | $15K | |
| 84134 | <1% | 1,957 | $15K | |
| 99385 | <1% | 244 | $15K | |
| 86665 | <1% | 820 | $15K | |
| 80069 | <1% | 3,109 | $14K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 178 | $14K |
| 95816 | <1% | 308 | $14K | |
| 64642 | <1% | 54 | $13K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 24 | $13K |
| 57522 | <1% | 12 | $13K | |
| 72146 | <1% | 117 | $13K | |
| 86336 | <1% | 1,575 | $12K | |
| 70498 | <1% | 862 | $12K | |
| 19081 | <1% | 12 | $12K | |
| 82330 | <1% | 4,043 | $12K | |
| 87045 | <1% | 2,417 | $12K | |
| 81401 | <1% | 237 | $12K | |
| 82977 | <1% | 2,866 | $12K | |
| 86708 | <1% | 1,769 | $12K | |
| 74160 | <1% | 112 | $12K | |
| 76820 | <1% | 3,242 | $11K | |
| 83993 | <1% | 945 | $11K | |
| 84432 | <1% | 1,252 | $11K | |
| 86694 | <1% | 1,703 | $11K | |
| 86256 | <1% | 1,129 | $11K | |
| 85379 | <1% | 6,538 | $11K | |
| 82465 | <1% | 3,149 | $11K | |
| 87081 | <1% | 7,553 | $11K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 442 | $11K |
| 87209 | <1% | 1,189 | $10K | |
| 36591 | <1% | 2,258 | $10K | |
| 84630 | <1% | 1,394 | $10K | |
| 84305 | <1% | 843 | $10K | |
| 82157 | <1% | 741 | $10K | |
| 77301 | <1% | 13 | $10K | |
| 80164 | <1% | 1,901 | $10K | |
| 87449 | <1% | 1,698 | $10K | |
| 87205 | <1% | 6,233 | $10K | |
| 81270 | <1% | 175 | $9K | |
| 76813 | <1% | 663 | $9K | |
| 76885 | <1% | 204 | $9K | |
| 87324 | <1% | 1,635 | $9K | |
| 83498 | <1% | 933 | $9K | |
| 87428 | <1% | 324 | $9K | |
| 80050 | General health panel | <1% | 3,000 | $9K |
| 82270 | <1% | 466 | $9K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 712 | $9K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,603 | $9K |
| 81025 | <1% | 9,950 | $9K | |
| 86141 | <1% | 1,156 | $9K | |
| 86334 | <1% | 755 | $8K | |
| 96416 | <1% | 45 | $8K | |
| 83921 | <1% | 793 | $8K | |
| 87075 | <1% | 2,697 | $8K | |
| 90734 | <1% | 453 | $8K | |
| 84484 | <1% | 41,413 | $8K | |
| 73552 | <1% | 949 | $8K | |
| 82040 | <1% | 3,325 | $7K | |
| 83090 | <1% | 714 | $7K | |
| 70487 | <1% | 82 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 28 | $7K |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 948 | $7K |
| 86301 | <1% | 622 | $7K | |
| 31267 | <1% | 16 | $7K | |
| 12001 | <1% | 1,200 | $7K | |
| 87400 | <1% | 3,334 | $7K | |
| 87329 | <1% | 873 | $6K | |
| 82525 | <1% | 921 | $6K | |
| 84681 | <1% | 632 | $6K | |
| 88341 | <1% | 898 | $6K | |
| 73600 | <1% | 498 | $6K | |
| 87328 | <1% | 724 | $6K | |
| 90688 | <1% | 340 | $6K | |
| 72128 | <1% | 284 | $6K | |
| 85613 | <1% | 1,153 | $6K | |
| 85597 | <1% | 531 | $6K | |
| 87517 | <1% | 211 | $6K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 131 | $6K |
| 72158 | <1% | 51 | $6K | |
| 85018 | <1% | 5,808 | $6K | |
| 82374 | <1% | 4,420 | $5K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 64 | $5K |
| 82671 | <1% | 253 | $5K | |
| 64483 | <1% | 14 | $5K | |
| 80197 | <1% | 641 | $5K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,880 | $5K |
| 87177 | <1% | 1,187 | $5K | |
| 87902 | <1% | 87 | $5K | |
| 83010 | <1% | 959 | $5K | |
| 82088 | <1% | 214 | $5K | |
| 82952 | <1% | 2,113 | $5K | |
| 86364 | <1% | 608 | $5K | |
| 73100 | <1% | 428 | $5K | |
| 85045 | <1% | 2,984 | $5K | |
| 82310 | <1% | 2,399 | $5K | |
| 70480 | <1% | 79 | $5K | |
| 84480 | <1% | 470 | $5K | |
| 77338 | <1% | 32 | $5K | |
| 74247 | <1% | 48 | $4K | |
| 83630 | <1% | 526 | $4K | |
| 85660 | <1% | 1,404 | $4K | |
| 82140 | <1% | 1,453 | $4K | |
| 88312 | <1% | 312 | $4K | |
| 86664 | <1% | 492 | $4K | |
| 86923 | <1% | 894 | $4K | |
| 86300 | <1% | 315 | $4K | |
| 73060 | <1% | 571 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,333 | $4K |
| 83014 | <1% | 989 | $4K | |
| 82164 | <1% | 582 | $4K | |
| 73120 | <1% | 192 | $4K | |
| 70544 | <1% | 13 | $4K | |
| 86663 | <1% | 440 | $4K | |
| 12011 | <1% | 648 | $4K | |
| 84075 | <1% | 1,428 | $4K | |
| 86618 | <1% | 383 | $4K | |
| 90677 | <1% | 13 | $3K | |
| 58301 | <1% | 31 | $3K | |
| 12002 | <1% | 709 | $3K | |
| 80305 | <1% | 6,365 | $3K | |
| 90474 | <1% | 1,057 | $3K | |
| 86709 | <1% | 635 | $3K | |
| 82962 | <1% | 15,276 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 154 | $3K |
| 29125 | <1% | 111 | $3K | |
| 80177 | <1% | 1,004 | $3K | |
| 84132 | <1% | 7,101 | $3K | |
| 90671 | <1% | 12 | $3K | |
| 85306 | <1% | 350 | $3K | |
| 87641 | <1% | 231 | $3K | |
| 77280 | <1% | 44 | $3K | |
| 62270 | <1% | 12 | $3K | |
| 82626 | <1% | 189 | $3K | |
| 86308 | <1% | 2,181 | $3K | |
| 87640 | <1% | 220 | $3K | |
| 82672 | <1% | 278 | $3K | |
| 87040 | <1% | 5,720 | $3K | |
| 94761 | <1% | 3,169 | $3K | |
| 77290 | <1% | 13 | $3K | |
| 81002 | <1% | 1,331 | $3K | |
| 0072A | <1% | 69 | $3K | |
| 84155 | <1% | 1,522 | $2K | |
| 84207 | <1% | 159 | $2K | |
| 90746 | <1% | 37 | $2K | |
| 82731 | <1% | 100 | $2K | |
| 86920 | <1% | 420 | $2K | |
| 90656 | <1% | 111 | $2K | |
| 85245 | <1% | 180 | $2K | |
| 83521 | <1% | 134 | $2K | |
| 99495 | <1% | 40 | $2K | |
| 0071A | <1% | 60 | $2K | |
| 86812 | <1% | 140 | $2K | |
| 81514 | <1% | 14 | $2K | |
| 78014 | <1% | 12 | $2K | |
| 85303 | <1% | 287 | $2K | |
| 82668 | <1% | 189 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 437 | $2K |
| 86060 | <1% | 465 | $2K | |
| 75574 | <1% | 25 | $2K | |
| 84244 | <1% | 168 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 232 | $2K |
| 29515 | <1% | 43 | $2K | |
| 94060 | <1% | 12 | $2K | |
| 85014 | <1% | 2,846 | $2K | |
| 82575 | <1% | 373 | $2K | |
| 86340 | <1% | 192 | $2K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 905 | $2K |
| 74740 | <1% | 15 | $2K | |
| 0124A | <1% | 63 | $2K | |
| 84436 | <1% | 387 | $2K | |
| 91322 | <1% | 12 | $2K | |
| 74230 | <1% | 24 | $2K | |
| 99386 | <1% | 27 | $2K | |
| 76981 | <1% | 129 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 28 | $2K |
| 92611 | <1% | 37 | $2K | |
| 76775 | <1% | 151 | $2K | |
| 83721 | <1% | 241 | $2K | |
| 84166 | <1% | 166 | $2K | |
| 87184 | <1% | 577 | $2K | |
| 86705 | <1% | 211 | $1K | |
| 93978 | <1% | 13 | $1K | |
| 87106 | <1% | 218 | $1K | |
| 64400 | <1% | 12 | $1K | |
| 80178 | <1% | 481 | $1K | |
| 86593 | <1% | 547 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,111 | $1K |
| 82390 | <1% | 214 | $1K | |
| C1758 | Catheter, ureteral | <1% | 311 | $1K |
| 87338 | <1% | 195 | $1K | |
| 93922 | <1% | 274 | $1K | |
| 82172 | <1% | 91 | $1K | |
| 86777 | <1% | 146 | $1K | |
| 83605 | <1% | 9,569 | $1K | |
| 87535 | <1% | 53 | $1K | |
| 74170 | <1% | 13 | $1K | |
| 84154 | <1% | 116 | $1K | |
| 90480 | <1% | 26 | $1K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 160 | $1K |
| 80202 | <1% | 301 | $1K | |
| 90461 | <1% | 3,522 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $998.32 |
| 88262 | <1% | 81 | $995.54 | |
| 85055 | <1% | 58 | $974.68 | |
| 88173 | <1% | 404 | $942.39 | |
| 85240 | <1% | 97 | $922.08 | |
| 93976 | <1% | 16 | $919.34 | |
| 73620 | <1% | 126 | $916.52 | |
| 74420 | <1% | 279 | $908.79 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 84 | $886.71 |
| 84238 | <1% | 40 | $859.30 | |
| 97168 | <1% | 27 | $853.35 | |
| 85384 | <1% | 633 | $845.85 | |
| 85300 | <1% | 132 | $812.28 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $789.26 |
| 84145 | <1% | 1,741 | $788.97 | |
| 82805 | <1% | 883 | $751.35 | |
| 80185 | <1% | 208 | $743.50 | |
| 87181 | <1% | 269 | $736.50 | |
| 85461 | <1% | 434 | $690.29 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 46,245 | $681.49 |
| 84295 | <1% | 4,522 | $663.30 | |
| 99406 | <1% | 43 | $631.51 | |
| 73070 | <1% | 87 | $622.56 | |
| 89051 | <1% | 350 | $621.00 | |
| 93225 | <1% | 13 | $603.24 | |
| 96376 | <1% | 18,055 | $574.76 | |
| 87015 | <1% | 506 | $566.95 | |
| 82239 | <1% | 61 | $545.56 | |
| 82435 | <1% | 4,132 | $539.43 | |
| 74150 | <1% | 14 | $539.16 | |
| 72114 | <1% | 12 | $538.48 | |
| 90658 | <1% | 33 | $536.58 | |
| 87420 | <1% | 926 | $522.47 | |
| 72220 | <1% | 49 | $506.05 | |
| 83520 | <1% | 656 | $502.23 | |
| 82103 | <1% | 66 | $501.13 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 39,181 | $469.70 |
| 81241 | <1% | 14 | $465.13 | |
| 87102 | <1% | 235 | $464.08 | |
| 83718 | <1% | 89 | $462.56 | |
| 0003A | <1% | 13 | $461.03 | |
| 86922 | <1% | 92 | $441.47 | |
| 82010 | <1% | 2,136 | $431.02 | |
| 84703 | <1% | 234 | $414.10 | |
| 94760 | <1% | 7,975 | $398.27 | |
| 86005 | <1% | 73 | $393.51 | |
| 85246 | <1% | 41 | $379.43 | |
| 83695 | <1% | 40 | $360.87 | |
| 87252 | <1% | 27 | $358.71 | |
| 87116 | <1% | 168 | $358.06 | |
| 87088 | <1% | 152 | $357.27 | |
| 83835 | <1% | 28 | $326.58 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 24,185 | $324.60 |
| 85244 | <1% | 26 | $321.99 | |
| 76821 | <1% | 413 | $301.39 | |
| 90681 | <1% | 556 | $295.20 | |
| 70160 | <1% | 13 | $292.08 | |
| 73521 | <1% | 16 | $289.45 | |
| 87430 | <1% | 3,671 | $278.86 | |
| 87206 | <1% | 207 | $256.49 | |
| 88302 | <1% | 76 | $254.10 | |
| 82077 | <1% | 665 | $249.43 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 149 | $244.40 |
| 86258 | <1% | 15 | $216.86 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 71 | $215.55 |
| 58300 | <1% | 12 | $212.37 | |
| 90473 | <1% | 68 | $206.13 | |
| 96127 | <1% | 44 | $188.10 | |
| 86341 | <1% | 15 | $177.36 | |
| 86580 | <1% | 29 | $177.19 | |
| 90723 | <1% | 3,829 | $175.00 | |
| 86880 | <1% | 12 | $168.01 | |
| 94010 | <1% | 25 | $164.57 | |
| C1729 | Catheter, drainage | <1% | 57 | $160.00 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 1,381 | $160.00 |
| 80159 | <1% | 17 | $157.11 | |
| 90715 | <1% | 5,464 | $156.90 | |
| 71100 | <1% | 12 | $144.99 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 14 | $144.04 |
| 36600 | <1% | 12 | $136.55 | |
| 93308 | <1% | 14 | $130.30 | |
| 85347 | <1% | 1,730 | $127.33 | |
| 82542 | <1% | 175 | $126.42 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 2,497 | $126.00 |
| 88313 | <1% | 12 | $114.72 | |
| 87350 | <1% | 15 | $110.29 | |
| 86645 | <1% | 12 | $109.80 | |
| 87341 | <1% | 27 | $107.35 | |
| 84163 | <1% | 21 | $106.29 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 12 | $105.33 |
| 86707 | <1% | 14 | $103.35 | |
| 85048 | <1% | 57 | $97.90 | |
| 92610 | <1% | 13 | $97.82 | |
| 86644 | <1% | 12 | $93.74 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 19 | $90.25 |
| 82044 | <1% | 63 | $80.99 | |
| 83625 | <1% | 14 | $79.47 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16,397 | $77.20 |
| 96040 | <1% | 304 | $71.67 | |
| 85041 | <1% | 30 | $60.81 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 9,966 | $59.04 |
| 76827 | <1% | 40 | $57.30 | |
| 87185 | <1% | 58 | $49.60 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 18,974 | $48.64 |
| 88311 | <1% | 56 | $48.43 | |
| 83930 | <1% | 13 | $41.71 | |
| 87076 | <1% | 13 | $41.56 | |
| 85007 | <1% | 27 | $39.12 | |
| 89050 | <1% | 50 | $29.86 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,408 | $18.37 |
| 85732 | <1% | 13 | $15.37 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,538 | $15.34 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 828 | $15.20 |
| 86703 | <1% | 26 | $14.41 | |
| 82945 | <1% | 65 | $13.53 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 4,020 | $12.62 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,994 | $11.12 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,337 | $10.85 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 191 | $10.78 |
| 84300 | <1% | 13 | $10.23 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 30,462 | $10.01 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 12,524 | $9.49 |
| 99177 | <1% | 184 | $8.92 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,560 | $8.71 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 561 | $8.71 |
| 84157 | <1% | 63 | $8.48 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 7,655 | $8.34 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 959 | $7.79 |
| 96368 | <1% | 774 | $7.28 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 80 | $6.24 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,307 | $4.75 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 223 | $4.03 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,571 | $3.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 27,318 | $2.84 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,004 | $2.57 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26,487 | $1.95 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,609 | $1.23 |
| J7999 | Compounded drug, not otherwise classified | <1% | 182 | $1.19 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,664 | $1.01 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,415 | $0.78 |
| J2704 | Injection, propofol, 10 mg | <1% | 25,926 | $0.68 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,553 | $0.37 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 29 | $0.33 |
| 36416 | <1% | 1,843 | $0.25 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,712 | $0.14 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,776 | $0.03 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 72 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 543 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 1,089 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,972 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 120 | $0.00 |
| 94729 | 0% | 799 | $0.00 | |
| 93325 | 0% | 1,018 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,667 | $0.00 |
| 90633 | 0% | 2,778 | $0.00 | |
| 82800 | 0% | 294 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 1,149 | $0.00 |
| 90700 | 0% | 883 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 1,013 | $0.00 |
| 99152 | 0% | 158 | $0.00 | |
| 80143 | 0% | 1,094 | $0.00 | |
| 90707 | 0% | 1,916 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,130 | $0.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 277 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 330 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 590 | $0.00 |
| 58340 | 0% | 44 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 1,769 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 406 | $0.00 |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 406 | $0.00 |
| 80179 | 0% | 1,082 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 119 | $0.00 |
| 94727 | 0% | 189 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 59 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 116 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 150 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 834 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 17 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 407 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 184 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 30 | $0.00 |
| 91312 | 0% | 63 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 12 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 365 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 167 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 175 | $0.00 |
| 64643 | 0% | 52 | $0.00 | |
| 82375 | 0% | 21 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 12 | $0.00 |
| 91300 | 0% | 36 | $0.00 | |
| 82397 | 0% | 12 | $0.00 | |
| 59426 | 0% | 12 | $0.00 | |
| 77012 | 0% | 12 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 24 | $0.00 |
| 90647 | 0% | 3,562 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 368 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 105 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 4,264 | $0.00 |
| 90696 | 0% | 758 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 320 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 195 | $0.00 |
| 93320 | 0% | 125 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 1,681 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 1,156 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 255 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 3,145 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 197 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 2,555 | $0.00 |
| 74430 | 0% | 30 | $0.00 | |
| 84270 | 0% | 1,402 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 3,249 | $0.00 |
| 90680 | 0% | 3,046 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 3,060 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 103 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 236 | $0.00 |
| 83883 | 0% | 122 | $0.00 | |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 480 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 82 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 617 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 884 | $0.00 |
| 92558 | 0% | 71 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 938 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 105 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 222 | $0.00 |
| 87450 | 0% | 26 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 58 | $0.00 |
| 36410 | 0% | 96 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 56 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,939 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 104 | $0.00 |
| 96377 | 0% | 49 | $0.00 | |
| 0346T | 0% | 25 | $0.00 | |
| J9045 | Injection, carboplatin, 50 mg | 0% | 48 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 48 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 65 | $0.00 |
| 90632 | 0% | 25 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 230 | $0.00 |
| 91307 | 0% | 151 | $0.00 | |
| C2618 | Probe/needle, cryoablation | 0% | 12 | $0.00 |
| 76377 | 0% | 24 | $0.00 | |
| 81050 | 0% | 18 | $0.00 | |
| 82803 | 0% | 14 | $0.00 | |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | 0% | 31 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 800 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 19 | $0.00 |
| 83874 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.